Rupatadine: Difference between revisions
Jump to navigation
Jump to search
Brian Blank (talk | contribs) No edit summary |
m Protected "Rupatadine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
(No difference)
|
Revision as of 18:58, 27 September 2011
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | |
Pharmacokinetic data | |
Protein binding | 99% |
Metabolism | Hepatic, CYP-mediated |
Elimination half-life | 5.9 hours |
Excretion | Fecal (60.9%) and renal (34.6%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C26H26ClN3 |
Molar mass | 415.958 g/mol |
Overview
Rupatadine is a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. Ruptatadine is marketed by Panacea-Biotech under the trade name Ralif. Ralif is approved for the treatment of allergic rhinitis.
External links
Categories:
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- H1 receptor antagonists